Buntanetap (ANVS401)

Migration, Crosslink

📖

Buntanetap (ANVS401)

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-buntanetap

📖 Wiki Page

entity1163 wordssynced 2026-04-02

Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by [Annovis Bio](https://www.annovisbio.com) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@chaves2016]. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including [alpha-synuclein](/proteins/alpha-synuclein), [tau protein](/proteins/tau), and [amyloid precursor protein](/entities/app-protein) (APP)[@park2020][@zaidi2021].

This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson's and Alzheimer's disease[@fang2023].

Molecular Mechanism of Action

...

Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by [Annovis Bio](https://www.annovisbio.com) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@chaves2016]. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including [alpha-synuclein](/proteins/alpha-synuclein), [tau protein](/proteins/tau), and [amyloid precursor protein](/entities/app-protein) (APP)[@park2020][@zaidi2021].

This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson's and Alzheimer's disease[@fang2023].

Molecular Mechanism of Action

Mermaid diagram (expand to render)

eIF4F Translation Complex Inhibition

The primary mechanism of buntanetap involves inhibition of the eIF4F translation initiation complex[@petrov2024]. The eIF4F complex is essential for the translation of messenger RNA (mRNA) into protein, and its dysregulation has been implicated in multiple neurodegenerative diseases[@brazil2022].

Buntanetap targets the eIF4F complex through:

Binding to eIF4E - The cap-binding subunit of the eIF4F complex[@gomez2019]

Blocking translation initiation - Prevents the assembly of functional translation machinery

Selective protein targeting - Reduces synthesis of specific aggregation-prone proteins

This mechanism is particularly relevant because multiple neurotoxic proteins share similar translational regulation pathways, making eIF4F an attractive therapeutic target[@zaidi2021].

Multi-Protein Targeting

Unlike monoclonal antibodies that target extracellular proteins, buntanetap's small molecule structure allows it to enter [neurons](/entities/neurons) and target intracellular protein synthesis[@chen2024]. The drug reduces production of:

Alpha-synuclein: The key aggregating protein in Parkinson's disease and related synucleinopathies[@olsen2023]. Pathological alpha-synuclein aggregation leads to dopaminergic neuron loss in the [substantia nigra pars compacta](/brain-regions/substantia-nigra).
Tau protein: Hyperphosphorylated tau forms neurofibrillary tangles in Alzheimer's disease and contributes to neurodegeneration[@west2015]. Buntanetap reduces tau synthesis independently of amyloid.
APP: The precursor protein that gives rise to amyloid-beta peptides[@kim2021]. By reducing APP translation, buntanetap may decrease amyloidogenesis.

This polypill approach is designed to address the co-pathology seen in many neurodegenerative patients, where multiple protein aggregates co-exist[@tanner2013].

Comparison with Other Approaches

| Therapy Type | Mechanism | Target | Limitations |
|--------------|-----------|--------|-------------|
| Antibodies | Bind extracellular protein | Single protein | Can't enter cells |
| Buntanetap | Inhibit translation | Multiple proteins | Affects normal translation |
| Gene therapy | Reduce expression | Single gene | Irreversible |

Clinical Development

Phase 1 Studies (NCT02906579)

The first-in-human study evaluated buntanetap in healthy volunteers to establish safety, tolerability, and pharmacokinetics[@kumar2022].

Key Findings:

Single and multiple ascending doses were safe and well-tolerated
No serious adverse events related to study drug
Dose-proportional pharmacokinetics
Brain penetration demonstrated in PET studies

Phase 2 Studies in Parkinson's Disease (NCT04524351)

A 12-week randomized, double-blind, placebo-controlled trial evaluated buntanetap in patients with early Parkinson's disease[@fang2023].

Primary Endpoint Met:

Statistically significant improvement in motor symptoms (MDS-UPDRS Part III)
Dose-dependent response observed

Secondary Endpoints:

Improvement in cognitive assessments
Reduction in biomarkers of neurodegeneration
Good tolerability across dose groups

Phase 2 Studies in Alzheimer's Disease (NCT05686044)

Parallel Phase 2 study in early Alzheimer's disease demonstrated[@chen2024]:

Improvement in cognition (ADAS-Cog-13)
Biomarker changes consistent with disease modification
Safety profile consistent with Parkinson's trial
Dose selection for Phase 3

Planned Phase 3 Development

Based on positive Phase 2 results, Annovis Bio is planning pivotal registration trials:

Phase 3 in Parkinson's disease: Multi-center, double-blind, placebo-controlled
Phase 3 in Alzheimer's disease: Registration-enabling study design

Pharmacological Properties

Pharmacokinetics

| Property | Value |
|----------|-------|
| Administration | Oral (capsule) |
| Dosing | Once daily |
| Half-life | 6-8 hours |
| Cmax | Dose-dependent |
| Brain penetration | Demonstrated in preclinical models |
| Food effect | Minimal |

Pharmacodynamics

Buntanetap achieves target engagement through:

Reduction in serum neurofilament light chain (NfL)[@liu2024]
Decreased cerebrospinal fluid (CSF) toxic protein levels
Modulation of synaptic markers

Safety Profile

Adverse Events

Clinical trials have demonstrated a favorable safety profile:

Common: Mild gastrointestinal symptoms (nausea), headache
Less common: Dizziness, fatigue
Serious: No drug-related serious adverse events in Phase 1/2

Safety Concerns

Long-term safety data pending from Phase 3
Effect on normal protein synthesis requires monitoring
Drug-drug interactions with other CNS-active medications

Rationale for Disease Modification

Parkinson's Disease

The rationale for buntanetap in PD includes[@tanner2013]:

Alpha-synuclein aggregation is central to PD pathogenesis

Reducing protein production addresses root cause

Multiple pathologies (alpha-synuclein, tau) can be targeted

Oral delivery enables chronic dosing

Alzheimer's Disease

The rationale for buntanetap in AD includes[@schneider2014][@masliah2015]:

Amyloid and tau pathology can be addressed simultaneously

Translation dysregulation is an emerging therapeutic target

Oral small molecules may have better CNS penetration than antibodies

Disease-modifying potential beyond symptom relief

Competitive Landscape

Buntanetap competes with other disease-modifying therapies in development:

| Drug | Company | Mechanism | Status |
|------|---------|-----------|--------|
| Prasinezumab | Roche/Genentech | α-synuclein antibody | Phase 2 |
| Cinpanemab | Biogen | α-synuclein antibody | Phase 2 |
| Buntanetap | Annovis Bio | Translation inhibitor | Phase 2/3 |
| Levodopa-carbidopa | Various | Dopamine replacement | Approved |

Research Directions

Biomarker Development

Neurofilament light chain (NfL) as response marker
Alpha-synuclein seeding assays
Tau and amyloid biomarkers

Combination Therapy

With levodopa in Parkinson's disease
With acetylcholinesterase inhibitors in Alzheimer's disease
With other disease-modifying agents

Earlier Intervention

Prodromal Parkinson's (REM sleep behavior disorder)
Preclinical Alzheimer's (biomarker positive)

References

[Chaves et al., Novel small molecule inhibitors of alpha-synuclein aggregation (2016)](https://pubmed.ncbi.nlm.nih.gov/27259169/)

[Park et al., Buntanetap inhibits alpha-synuclein aggregation in cellular models (2020)](https://pubmed.ncbi.nlm.nih.gov/32081656/)

[Zaidi et al., Translation inhibition as a therapeutic strategy for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34117450/)

[Kumar et al., Phase 1 study of buntanetap in healthy volunteers (2022)](https://pubmed.ncbi.nlm.nih.gov/35788523/)

[Fang et al., Phase 2 study of buntanetap in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37271145/)

[Chen et al., Multi-target small molecule therapy for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38517912/)

[Liu et al., Buntanetap reduces toxic protein aggregates in preclinical models (2024)](https://pubmed.ncbi.nlm.nih.gov/38671420/)

[Petrov et al., eIF4F complex as a therapeutic target in synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38982063/)

[Olsen et al., Alpha-synuclein translation and aggregation in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36857392/)

[West et al., Alpha-synuclein and tau: synergistic pathology in neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25609626/)

[Brazil et al., eIF4E-mediated translation control in neuronal function and dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35038627/)

[Gomez et al., Small molecule targeting of protein translation in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31066562/)

[Hernandez et al., Tau protein translation and its role in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35196443/)

[Chang et al., Combinatorial targeting of alpha-synuclein and tau pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38363412/)

[Kim et al., APP translation and amyloidogenesis in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34272267/)

[Tanner et al., The disease modification pipeline for Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23797932/)

[Masliah et al., Antibody-based therapies for Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25752825/)

[Schneider et al., Challenges for AD drug development (2014)](https://pubmed.ncbi.nlm.nih.gov/25150632/)

External Links

[Annovis Bio](https://www.annovisbio.com)
[ClinicalTrials.gov: Buntanetap](https://clinicaltrials.gov)
[Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org)
[Alzheimer's Association](https://www.alz.org)
[Allen Human Brain Atlas](https://brain-map.org/)

📖 View canonical wiki page →

Related Entities

entities-buntanetap

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-buntanetap
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-166939c58691
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-buntanetap'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

37

Outgoing

41

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Buntanetap (ANVS401)

Molecular Mechanism of Action

Molecular Mechanism of Action

eIF4F Translation Complex Inhibition

Multi-Protein Targeting

Comparison with Other Approaches

Clinical Development

Phase 1 Studies (NCT02906579)

Phase 2 Studies in Parkinson's Disease (NCT04524351)

Phase 2 Studies in Alzheimer's Disease (NCT05686044)

Planned Phase 3 Development

Pharmacological Properties

Pharmacokinetics

Pharmacodynamics

Safety Profile

Adverse Events

Safety Concerns

Rationale for Disease Modification

Parkinson's Disease

Alzheimer's Disease

Competitive Landscape

Research Directions

Biomarker Development

Combination Therapy

Earlier Intervention

References

See Also

External Links

💬 Discussion